Cell signaling

CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Arizona to Help Combat Opioid Abuse

Retrieved on: 
Wednesday, June 20, 2018
Woonsocket, Rhode Island, Chemistry, Organic chemistry, CVS Pharmacy, CVS Health, Cell signaling, Naloxone, CVS, Opioid use disorder, Mark Brnovich, Concurrent Versions System, ARIZONA

Arizona Attorney General Mark Brnovich attended the launch of the program at a Phoenix CVS Pharmacy location.

Key Points: 
  • Arizona Attorney General Mark Brnovich attended the launch of the program at a Phoenix CVS Pharmacy location.
  • The 13 new medication disposal units installed in CVS Pharmacy locations across the state supplement the units CVS Health has donated to local law enforcement departments in Kingman, Tolleson and Wellton.
  • The extension of CVS Health's safe medication disposal program in Arizona is part of the expansion of 750 safe medication disposal units to CVS Pharmacy locations across the U.S. and other enhancements to the company's strategy to address and prevent opioid abuse, announced in September 2017 .
  • CVS Health has also worked to expand access to the opioid overdose-reversal drug naloxone in 46 states, including Arizona.

Zubsolv® Now Launched in the EU, Which Triggers a EUR 3m Milestone Payment to Orexo

Retrieved on: 
Monday, June 18, 2018
Chemistry, Cell signaling, Morphinans, RTT, Signal transduction, Opioid antagonists, Drug rehabilitation, Alcohols, Naloxone, Buprenorphine

The launch is triggering a milestone payment of EUR 3 million from Mundipharma.

Key Points: 
  • The launch is triggering a milestone payment of EUR 3 million from Mundipharma.
  • [2]
    "Taking the step out in Europe, is yet another important milestone for Orexo.
  • Zubsolv will be an affordable and user-friendly treatment and the first therapy in Europe with a choice of up to six different strengths.
  • The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv.

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market

Retrieved on: 
Friday, June 15, 2018
Chemistry, RTT, Cell signaling, Morphinans, Organic chemistry, Alcohols, Drug rehabilitation, Opioid antagonists, Buprenorphine, Naloxone, Buprenorphine/naloxone, Opioid use disorder

Injecting Buprenorphine and Naloxone Sublingual Film may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.

Key Points: 
  • Injecting Buprenorphine and Naloxone Sublingual Film may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.
  • Do not take Buprenorphine and Naloxone Sublingual Film if you are allergic to buprenorphine or naloxone.
  • What should I tell my healthcare provider before taking Buprenorphine and Naloxone Sublingual Film?
  • Before taking Buprenorphine and Naloxone Sublingual Film, tell your doctor if you currently have or are:

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

Retrieved on: 
Thursday, June 14, 2018
Chemistry, Cell signaling, Morphinans, RTT, Neurochemistry, Alcohols, Drug rehabilitation, Opioid antagonists, Buprenorphine, Naloxone, Food and Drug Administration, Opioid use disorder

That includes promoting the development of better drugs, and also facilitating market entry of generic versions of approved drugs to help ensure broader access," said FDA Commissioner Scott Gottlieb, M.D.

Key Points: 
  • That includes promoting the development of better drugs, and also facilitating market entry of generic versions of approved drugs to help ensure broader access," said FDA Commissioner Scott Gottlieb, M.D.
  • When coupled with other social, medical and psychological services, medication-assisted treatments are often the most effective approach for opioid dependence."
  • One of the ways the FDA is encouraging access and wider use of MAT is through the approval of generic versions of these products.
  • Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Emergency Departments Help Close Gaps in Opioid Abuse and Addiction Treatment

Retrieved on: 
Thursday, June 14, 2018
Chemistry, RTT, Cell signaling, Morphinans, Neurochemistry, Substance dependence, Drug rehabilitation, Ethers, Buprenorphine, Opioid use disorder, Opioid, Addiction

MAT refers to addiction treatment with medications, most commonly buprenorphine, although it is most effective when combined with behavioral therapy and counseling.

Key Points: 
  • MAT refers to addiction treatment with medications, most commonly buprenorphine, although it is most effective when combined with behavioral therapy and counseling.
  • Coordinated care for complex chronic conditions is proven to be effective; treating opioid use disorder should be no different."
  • The authors make recommendations for opioid abuse screening, treatment and referrals in the emergency department.
  • Annals of Emergency Medicineis the peer-reviewed scientific journal for the American College of Emergency Physicians, the national medical society representing emergency medicine.

Global Nitric Oxide Therapy Systems (Portable & Fixed) Market 2017-2026 - Market is Expected to Expand at a CAGR of 5.19%

Retrieved on: 
Thursday, June 14, 2018
Neurochemistry, Chemistry, Cell signaling, NMDA receptor antagonists, Gaseous signaling molecules, Nitrogen cycle, GABAA receptor positive allosteric modulators, Oxides, Nitric oxide, Acute respiratory distress syndrome, Ketamine, Biological functions of nitric oxide

The global nitric oxide therapy systems market is expected to expand at a CAGR of 5.19% from 2017 to 2026.

Key Points: 
  • The global nitric oxide therapy systems market is expected to expand at a CAGR of 5.19% from 2017 to 2026.
  • Durability and lightweight are the meritorious features that increase the demand for portable nitric oxide therapy systems.
  • North America is the market leader in nitric oxide therapy systems due to the rising prevalence of acute respiratory distress syndrome in the adult population and the presence of key players actively engaged in the manufacturing of nitric oxide therapy systems.
  • Competitive market formed due to the emergence of local providers of nitric oxide therapy systems contribute to the growth of Asia Pacific market.

CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Virginia to Help Combat Opioid Abuse

Retrieved on: 
Thursday, June 14, 2018
Chemistry, Woonsocket, Rhode Island, Organic chemistry, CVS Pharmacy, Cell signaling, CVS Health, Naloxone, CVS, Pharmacy, Larry Merlo

The 32 new medication disposal units will be installed in CVS Pharmacy locations across the state, supplementing the 64 units CVS Health has donated to local law enforcement departments in Virginia.

Key Points: 
  • The 32 new medication disposal units will be installed in CVS Pharmacy locations across the state, supplementing the 64 units CVS Health has donated to local law enforcement departments in Virginia.
  • I want to thank CVS Health for being proactive and I would encourage more pharmacies to install safe drug disposal units across the Commonwealth."
  • CVS Health has also worked to expand access to the opioid overdose-reversal drug naloxone in 46 states, including Virginia.
  • CVS Health is a pharmacy innovation company helping people on their path to better health.

Cendyn integrates with Sitecore via Hedgehog to elevate real-time marketing personalization

Retrieved on: 
Monday, June 11, 2018
Cell signaling, Evolutionary developmental biology, Hedgehog signaling pathway

The agreement will enable Hedgehog to tap Cendyn's guest intelligence engine to fuel live personalization and dynamic pricing based on marketing segmentation and guest profiles in eInsight across Sitecore's digital platforms.

Key Points: 
  • The agreement will enable Hedgehog to tap Cendyn's guest intelligence engine to fuel live personalization and dynamic pricing based on marketing segmentation and guest profiles in eInsight across Sitecore's digital platforms.
  • The arrangement also includes a re-seller agreement with Hedgehog that promotes the sale of Cendyn eInsight as the preferred CRM of choice for hoteliers to Hedgehog customers.
  • "Our partnership with Hedgehog for Sitecore CXP integration is a big step forward in helping hotels deliver personalization at scale based on business impact," says Charles Deyo, President & CEO at Cendyn.
  • "The partnership between Hedgehog and Cendyn really spotlights our focus on personalization in the travel and hospitality industry," says Dan Galvez, Founder and CEO at Hedgehog.

Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules

Retrieved on: 
Monday, June 11, 2018
Chemistry, Nicotinic agonists, Teratogens, Cell signaling, Chemical bonding, Coordination chemistry, Cytisine, Nicotinic acetylcholine receptor, Ligand, Nicotine, Coordination complex, Binding selectivity

Molecular simulation of protein-ligand complexes was also used to understand how structural modifications might modify a ligand's activity profile.

Key Points: 
  • Molecular simulation of protein-ligand complexes was also used to understand how structural modifications might modify a ligand's activity profile.
  • "This effort led by the University of Bristol will enable Achieve to pursue the development of next-generation cytisine treatments, which will be highly-targeted and more potent.
  • The full publication, Unlocking Nicotinic Selectivity via Direct CH Functionalization of ()-Cytisine, is available via Open Access and can be viewed at https://doi.org/10.1016/j.chempr.2018.05.007 .
  • Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients.

First Ketamine Infusion Clinic in Palm Springs, CA Opens

Retrieved on: 
Friday, June 8, 2018
Neurochemistry, Medicine, Cell signaling, RTT, Anesthesia, General anesthetics, Abnormal psychology, Psychiatric diagnosis, Ketamine, Sedation, Treatment-resistant depression, Posttraumatic stress disorder

Now, some residents of Palm Springs and the Coachella Valley who suffer from chronic pain, anxiety disorders, post-traumatic stress disorder (PTSD), or treatment-resistant depression may find relief at Reset Ketamine.

Key Points: 
  • Now, some residents of Palm Springs and the Coachella Valley who suffer from chronic pain, anxiety disorders, post-traumatic stress disorder (PTSD), or treatment-resistant depression may find relief at Reset Ketamine.
  • Reset Ketamine uses low-dose ketamine infusions with continuous vital signs monitoring by a medical professional to relieve symptoms.
  • Dr. Samuel Ko , the founder of Reset Ketamine, uses this medicine frequently in the ER for procedural sedation.
  • Find out more about our company and the research behind ketamine infusions at www.resetketamine.com .